---
id: "entity-gsk"
type: "entity"
entityType: "organization"
canonicalName: "GSK"
aliases: ["GSK plc", "GlaxoSmithKline"]
source_timestamps: ["§ The 4C Framework for Building Generative Readiness"]
tags: ["pharmaceuticals", "case-study"]
related: ["concept-generative-listening-systems", "claim-guideline-format-change-impact", "entity-gold", "entity-openevidence", "quote-pharma-publication-standards"]
sources: ["geo"]
sourceVaultSlug: "hbr-seg-geo"
originDay: 3
articleStem: "hbr-tier1-01-gen-ai-b2b-buying"
sourceUrl: "https://hbr.org/2026/06/how-gen-ai-is-disrupting-b2b-buying-decisions"
sourceTitle: "How Gen AI is Disrupting B2B Buying Decisions"
---
# GSK

**GSK** (GSK plc, formerly GlaxoSmithKline) is a London-based global biopharmaceutical company focused on vaccines and specialty medicines (respiratory, HIV, immunology, oncology).

**Role in the source:** GSK is the flagship *pharma* case study for [[concept-generative-listening-systems]]. In 2025–26 it ran a generative-listening audit for a **COPD** treatment brand — testing **6,000 prompts across nine nodes** ([[action-conduct-generative-audit]]) — which revealed critical AI-visibility insights and uncovered the machine-readability failure of the [[entity-gold]] guidelines ([[claim-guideline-format-change-impact]]). GSK also engaged [[entity-openevidence]] to learn how pharma publication standards must evolve for LLMs ([[quote-pharma-publication-standards]]), a theme that connects to [[contrarian-paywalls-hurt-influence]] and open question [[question-publisher-ai-licensing]].

**Canonical context (enrichment):** Confirmed as a London-based global biopharma company (vaccines and specialty medicines) actively exploring AI for drug discovery, clinical development, and commercial analytics.